The divestiture strengthens MacroGenics' balance sheet and focuses resources on R&D. Monitor pipeline data readouts and potential partnerships, especially for lorigerlimab and TZIELD, as key catalysts.
Price Chart
Executive Summary
MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitioning to an asset-light R&D model and securing cash to fund its pipeline. The deal includes a supply agreement for continued production support.
Key Financial Metrics
Key Facts
- Sale of GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million
- Approximately 140 employees transferred to Bora
- Supply agreement signed for process development and production for MacroGenics' pipeline
Financial Impact
Proceeds of $122.5 million before expenses represent about 42% of market cap, providing significant cash runway.
Risk Factors
- Dependence on Bora for manufacturing could create supply chain risk
- Execution risk in transitioning to outsourced manufacturing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321364 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | 8-K | $4.57 $4.01 | ▼ −12.25% | ▼ −14.50% | $3.58 (−21.66%) |
Jul 2, 2026 13w ago | Press Release | $4.71 $3.78 | ▼ −19.75% | ▼ −19.33% | $3.58 (−23.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $3.96 $4.33 | ▲ +9.34% | ▲ +7.56% | $3.58 (−9.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.01 $4.57 | ▲ +13.97% | ▲ +12.07% | $3.58 (−10.72%) |
May 13, 2026 20w ago | 8-K | $4.16 $3.96 | ▼ −4.81% | ▼ −3.95% | $3.58 (−13.94%) |
May 12, 2026 20w ago | 8-K | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
May 11, 2026 20w ago | Press Release | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
Apr 8, 2026 25w ago | 8-K | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | Press Release | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | DEFA14A | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access